

Ferruccio Bonino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2366708/publications.pdf>

Version: 2024-02-01

249
papers

22,463
citations

17440

63
h-index

8630

146
g-index

252
all docs

252
docs citations

252
times ranked

9456
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages. <i>International Journal of Obesity</i> , 2022, 46, 50-58.	3.4	9
2	Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis. <i>Healthcare (Switzerland)</i> , 2022, 10, 374.	2.0	0
3	Evidence of a Gastro-Duodenal Effect on Adipose Tissue and Brain Metabolism, Potentially Mediated by Gut Liver Inflammation: A Study with Positron Emission Tomography and Oral 18FDG in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2659.	4.1	3
4	Liver and White/Brown Fat Dystrophy Associates with Gut Microbiota and Metabolomic Alterations in 3xTg Alzheimer's Disease Mouse Model. <i>Metabolites</i> , 2022, 12, 278.	2.9	0
5	Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine. <i>Viruses</i> , 2022, 14, 701.	3.3	6
6	Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1406.	2.4	1
7	A Deep Learning Approach for Hepatic Steatosis Estimation from Ultrasound Imaging. <i>Communications in Computer and Information Science</i> , 2021, , 703-714.	0.5	1
8	Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib. <i>Cancers</i> , 2021, 13, 2064.	3.7	3
9	Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet. <i>Nutrients</i> , 2021, 13, 3438.	4.1	5
10	Maternal High-Fat Feeding Affects the Liver and Thymus Metabolic Axis in the Offspring and Some Effects Are Attenuated by Maternal Diet Normalization in a Minipig Model. <i>Metabolites</i> , 2021, 11, 800.	2.9	1
11	Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1406-1416.	3.7	6
12	Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2020, 29, 189-196.	1.7	17
13	HBV pre-core mutant in genotype D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. <i>Journal of Medical Virology</i> , 2018, 90, 1232-1239.	5.0	8
14	Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1585-1596.	1.5	16
15	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. <i>World Journal of Hepatology</i> , 2018, 10, 231-245.	2.0	18
16	Low Anisakis-specific IgE prevalence in dyspeptic patients in Italy – a retrospective study. <i>The EuroBiotech Journal</i> , 2018, 2, 59-63.	1.0	0
17	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.9	254
18	Genome-Wide Comparison of Next-Generation Sequencing and qPCR Platforms for microRNA Profiling in Serum. <i>Methods in Molecular Biology</i> , 2017, 1580, 21-44.	0.9	17

#	ARTICLE	IF	CITATIONS
19	Long-term outcome of inactive and active, low viraemic HBsAg-negative hepatitis B virus infection: Benign course towards HBsAg clearance. <i>Liver International</i> , 2017, 37, 1622-1631.	3.9	51
20	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	4.1	126
21	New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases. <i>Digestive and Liver Disease</i> , 2016, 48, 536-541.	0.9	20
22	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.9	56
23	Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy. , 2016, , 303-321.		0
24	Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. <i>PLoS ONE</i> , 2015, 10, e0130209.	2.5	45
25	T cell receptor-therapy in HBV-related hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 4, e1008354.	4.6	34
26	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. <i>Journal of Hepatology</i> , 2015, 62, 486-491.	3.7	160
27	A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 249-254.	0.9	5
28	Reply to: "To target or not to target viral antigens in HBV related HCC?". <i>Journal of Hepatology</i> , 2015, 62, 1450-1452.	3.7	3
29	Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: An Italian position statement. <i>World Journal of Gastroenterology</i> , 2014, 20, 14642.	3.3	66
30	Interferon Therapy of Chronic Hepatitis B. <i>Intervirology</i> , 2014, 57, 163-170.	2.8	24
31	HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN±2a and Ribavirin: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 458-465.	2.0	19
32	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9
33	A Serum MicroRNA Signature Is Associated with the Immune Control of Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2014, 9, e110782.	2.5	41
34	Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. <i>Journal of Virological Methods</i> , 2013, 189, 110-117.	2.1	4
35	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. <i>Hepatology International</i> , 2013, 7, 88-97.	4.2	136
36	Occult Hepatitis B Virus (HBV) Infections: Hepatitis B Surface Antigen (HBsAg) Negative and Primary Occult. <i>Current Hepatitis Reports</i> , 2013, 12, 112-118.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype. <i>Journal of Hepatology</i> , 2013, 59, 1153-1159.	3.7	88
38	Impatto sul budget di un trattamento personalizzato dell'epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimana. <i>Pharmacoeconomics Italian Research Articles</i> , 2013, 15, 123-130.	0.2	0
39	Individualized treatment of HBeAg-negative CHB using peg-interferon alfa-2a as first-line and week 12 HBV-DNAHBsAg stopping rule. A cost-effectiveness analysis. <i>Antiviral Therapy</i> , 2013, 18, 623-633.	1.0	14
40	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1885-1897.	3.8	38
41	A novel method for banking dental pulp stem cells. <i>Transfusion and Apheresis Science</i> , 2012, 47, 199-206.	1.0	51
42	Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 414-418.	5.6	41
43	Circulating Hepatitis B Surface Antigen Particles Carry Hepatocellular microRNAs. <i>PLoS ONE</i> , 2012, 7, e31952.	2.5	58
44	Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay. <i>Vaccine Journal</i> , 2011, 18, 1943-1950.	3.1	35
45	Liver Stiffness, a Non-Invasive Marker of Liver Disease: A Core Study Group Report. <i>Antiviral Therapy</i> , 2010, 15, 69-78.	1.0	33
46	Diagnostic Markers of Chronic Hepatitis B Infection and Disease. <i>Antiviral Therapy</i> , 2010, 15, 35-44.	1.0	29
47	Conclusion to "Hepatitis B virus heterogeneity" a means to personalized care™. <i>Antiviral Therapy</i> , 2010, 15, 79-80.	1.0	0
48	From Actors to Authors. <i>Journal of Ambulatory Care Management</i> , 2010, 33, 231-240.	1.1	5
49	Decompensated Chronic Heart Failure: Increased Liver Stiffness Measured by Means of Transient Elastography. <i>Radiology</i> , 2010, 257, 872-878.	7.3	155
50	Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010, 42, 81-91.	0.9	56
51	Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers. <i>Gastroenterology</i> , 2010, 139, 483-490.	1.3	361
52	Introduction to "Hepatitis B virus heterogeneity" a means to personalized care™. <i>Antiviral Therapy</i> , 2010, 15, 1-2.	1.0	4
53	Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 1141-1150.	7.3	418
54	Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a. <i>Gastroenterology</i> , 2009, 136, 2169-2179.e4.	1.3	288

#	ARTICLE	IF	CITATIONS
55	Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 531.	3.3	19
56	Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 212-215.	4.7	15
57	Personalized therapy in chronic viral hepatitis. <i>Molecular Aspects of Medicine</i> , 2008, 29, 103-111.	6.4	5
58	Liver stiffness in the hepatitis B virus carrier: A non-invasive marker of liver disease influenced by the pattern of transaminases. <i>World Journal of Gastroenterology</i> , 2008, 14, 6154.	3.3	116
59	Thermal Care of Functional Dyspepsia Based on Bicarbonate-Sulphate-Calcium Water: A Sequential Clinical Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2007, 4, 381-391.	1.2	7
60	Predicting response to peginterferon α 2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2007, 56, 699-705.	12.1	240
61	Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 341-349.	3.0	22
62	Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. <i>Journal of Psychosomatic Research</i> , 2007, 62, 349-355.	2.6	27
63	Cytoplasmic Tubular Structures in Liver of HBsAg Carrier Chimpanzees Infected with Delta Agent and Comparison with Cytoplasmic Structures in Non-A, Non-B Hepatitis. <i>Hepatology</i> , 2007, 3, 631-637.	7.3	37
64	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	2.4	239
65	Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. <i>Journal of Viral Hepatitis</i> , 2007, 14, 360-369.	2.0	573
66	Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. <i>Liver International</i> , 2007, 27, 612-619.	3.9	30
67	Animal model for liver cell banking from non-heart beating donors after prolonged ischaemia time. <i>Digestive and Liver Disease</i> , 2006, 38, 905-911.	0.9	6
68	Alteration in the Transcriptional Profile of Livers from Brain-dead Organ Donors. <i>Transplantation</i> , 2006, 82, 69-79.	1.0	20
69	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	7.3	347
70	Reduced Expression of the Melanocortin-1 Receptor in Human Liver during Brain Death. <i>NeuroImmunoModulation</i> , 2006, 13, 51-55.	1.8	19
71	A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. <i>Antiviral Therapy</i> , 2006, 11, 197-212.	1.0	15
72	A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon- α 2A, Lamivudine and Combination Therapy. <i>Antiviral Therapy</i> , 2006, 11, 197-212.	1.0	46

#	ARTICLE	IF	CITATIONS
73	Validation and comparison of different PCR-based methods for detection of hepatitis B virus precore region mutants. <i>Journal of Virological Methods</i> , 2005, 129, 64-74.	2.1	1
74	Gene Expression Profiling Reveals Multiple Protective Influences of the Peptide Î±-Melanocyte-Stimulating Hormone in Experimental Heart Transplantation. <i>Journal of Immunology</i> , 2005, 175, 3391-3401.	0.8	23
75	Software and expert system for the management of chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2005, 34, S29-S33.	3.1	1
76	Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. <i>Journal of Hepatology</i> , 2005, 42, 61-67.	3.7	97
77	Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer. <i>Bone Marrow Transplantation</i> , 2004, 33, 1057-1059.	2.4	0
78	Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2004, 351, 1206-1217.	27.0	1,082
79	Treatment of Chronic Hepatitis B: From Research to Clinical Practice Via the Consensus Conferences. <i>Current Pharmaceutical Design</i> , 2004, 10, 2063-2075.	1.9	19
80	Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares. <i>Journal of Viral Hepatitis</i> , 2003, 10, 168-173.	2.0	12
81	Molecular analysis of VHL+ B lymphocytes in hepatitis C patients. <i>Digestive and Liver Disease</i> , 2003, 35, 788-794.	0.9	6
82	Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease. <i>Transplantation Proceedings</i> , 2003, 35, 1028-1029.	0.6	2
83	Liver transplantation in genetic defects of hepatocytes. <i>Transplantation Proceedings</i> , 2003, 35, 1049.	0.6	0
84	Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. <i>Journal of Hepatology</i> , 2003, 39, 160-163.	3.7	60
85	Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. <i>Journal of Hepatology</i> , 2003, 39, 164-167.	3.7	34
86	Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies. <i>The Hematology Journal</i> , 2003, 4, 321-327.	1.4	22
87	Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. <i>Antiviral Therapy</i> , 2003, 8, 519-30.	1.0	11
88	Sustained Response to Interferon-Ribavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase. <i>Antiviral Therapy</i> , 2003, 8, 519-530.	1.0	29
89	Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein. <i>Journal of Experimental Medicine</i> , 2002, 195, 35-42.	8.5	420
90	Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. <i>Journal of Hepatology</i> , 2002, 36, 263-270.	3.7	290

#	ARTICLE	IF	CITATIONS
91	Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines. <i>Digestive and Liver Disease</i> , 2002, 34, 396-397.	0.9	0
92	EFFECTS OF A BICARBONATE-ALKALINE MINERAL WATER ON GASTRIC FUNCTIONS AND FUNCTIONAL DYSPEPSIA: A PRECLINICAL AND CLINICAL STUDY. <i>Pharmacological Research</i> , 2002, 46, 525-531.	7.1	44
93	Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. <i>Transplantation Proceedings</i> , 2001, 33, 1355-1357.	0.6	127
94	Usefulness of IgM anti-HCV in differential diagnosis between recurrent hepatitis C and acute rejection in liver transplant patients. <i>Transplantation Proceedings</i> , 2001, 33, 3641-3642.	0.6	3
95	Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy. <i>Expert Review of Molecular Diagnostics</i> , 2001, 1, 310-314.	3.1	0
96	The Impact of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV): From Research to Clinical Practice. , 2000, 45, 99-112.		0
97	Foreword. <i>Transplantation Proceedings</i> , 2000, 32, 2691-2692.	0.6	0
98	Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study. <i>Digestive and Liver Disease</i> , 2000, 32, 211-216.	0.9	4
99	Living-donor liver transplantation: to be or not to be. <i>Digestive and Liver Disease</i> , 2000, 32, 243-244.	0.9	2
100	The hepatitis C virus carrier with "persistently" normal serum transaminases: a misleading clinical issue. <i>Digestive and Liver Disease</i> , 2000, 32, 603-604.	0.9	1
101	Hepatitis B Virus Mutants. <i>Intervirology</i> , 1999, 42, 69-80.	2.8	73
102	Long Term Response to Therapy of Chronic Anti-HBe"Positive Hepatitis B Is Poor Independent of Type and Schedule of Interferon. <i>American Journal of Gastroenterology</i> , 1999, 94, 1366-1372.	0.4	50
103	Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy. <i>Journal of Viral Hepatitis</i> , 1999, 6, 373-380.	2.0	0
104	High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. <i>Journal of Hepatology</i> , 1999, 31, 990-996.	3.7	15
105	Treatment of patients with chronic hepatitis C and cirrhosis. <i>Journal of Hepatology</i> , 1999, 31, 197-200.	3.7	10
106	Long term response to therapy of chronic anti-HBe"positive Hepatitis B is poor independent of type and schedule of interferon. <i>American Journal of Gastroenterology</i> , 1999, 94, 1366-1372.	0.4	48
107	Effect of interferon- β on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. <i>Lancet, The</i> , 1998, 351, 1535-1539.	13.7	280
108	Coupling to lactosaminated poly-L-lysine reduces the toxic effects of ribavirin on red blood cells. <i>Journal of Hepatology</i> , 1998, 29, 1032-1033.	3.7	12

#	ARTICLE	IF	CITATIONS
109	Hepatitis C Virus Heteroduplex Tracking Assay for Genotype Determination Reveals Diverging Genotype 2 Isolates in Italian Hemodialysis Patients. <i>Journal of Clinical Microbiology</i> , 1998, 36, 227-233.	3.9	22
110	IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 661-663.	1.6	18
111	Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: A pilot study. <i>Clinical and Diagnostic Virology</i> , 1997, 8, 63-70.	1.7	8
112	The prevalence of hepatitis C virus types in patients of the same geographic area, according to the source of infection and liver disease. <i>Clinical and Diagnostic Virology</i> , 1997, 8, 189-194.	1.7	5
113	Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. <i>Transplantation Proceedings</i> , 1997, 29, 519-521.	0.6	92
114	Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon. <i>Journal of Hepatology</i> , 1997, 26, 449-450.	3.7	9
115	A new hepatitis C virus-like flavivirus in patients with cryptogenic liver disease associated with elevated GGT and alkaline phosphatase serum levels. <i>Journal of Viral Hepatitis</i> , 1997, 4, 55-60.	2.0	35
116	Impact of interferon- α therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. <i>Journal of Viral Hepatitis</i> , 1997, 4, 79-82.	2.0	17
117	Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. <i>Archives of Virology</i> , 1997, 142, 535-544.	2.1	43
118	Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 1997, 4, 235-242.	2.0	6
119	Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. <i>Journal of Viral Hepatitis</i> , 1997, 4, 363-370.	2.0	45
120	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997, 51, 313-318.	5.0	63
121	Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. <i>Journal of Virology</i> , 1997, 71, 2241-2251.	3.4	101
122	Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. <i>Journal of Hepatology</i> , 1996, 25, 644-648.	3.7	39
123	Is Hepatitis C Virus RNA Detectable in Dialysis Ultrafiltrate?. <i>Nephron</i> , 1996, 72, 102-103.	1.8	4
124	Demonstration of specific detection of anti-HCV IgM core antibodies. <i>Journal of Virological Methods</i> , 1996, 59, 121-126.	2.1	3
125	Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease. <i>Journal of Viral Hepatitis</i> , 1996, 3, 301-306.	2.0	113
126	Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. <i>Hepatology</i> , 1996, 23, 657-661.	7.3	49

#	ARTICLE	IF	CITATIONS
127	High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders. <i>British Journal of Haematology</i> , 1996, 95, 204-211.	2.5	62
128	Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; Persistence of anti-HCV in children is associated with the mother's anti-HCV immunoblotting pattern. <i>Hepatology</i> , 1995, 21, 328-332.	7.3	91
129	Hepatitis C virus infection in patients with haematological diseases: evidence for the association with erythrocytes transfusion and liver disease. <i>International Hepatology Communications</i> , 1995, 4, 9-15.	0.7	2
130	Primary biliary cirrhosis: lung involvement. <i>Liver</i> , 1995, 15, 196-201.	0.1	14
131	Hepatotoxicity of intravenous Cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. <i>Liver</i> , 1995, 15, 320-323.	0.1	26
132	Precore Mutant Hepatitis B Virus and Outcome of Chronic Infection and Hepatitis in Hepatitis B e Antigen-Positive Children. <i>Pediatric Research</i> , 1994, 36, 347-350.	2.3	18
133	Quantitative analysis of wild-type and HBeAg minus hepatitis B viruses by a sequence-dependent primer extension assay. <i>Journal of Medical Virology</i> , 1994, 43, 310-315.	5.0	18
134	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	7.3	962
135	Recombinant interferon- α 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. <i>Hepatology</i> , 1994, 20, 287-290.	7.3	70
136	Expression of the c-myc protooncogene product in cells infected with the hepatitis delta virus. <i>Hepatology</i> , 1994, 20, 1109-1114.	7.3	2
137	Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose. <i>Journal of Hepatology</i> , 1994, 20, 307-309.	3.7	23
138	Long-term response to interferon- α 2b re-treatment in chronic hepatitis C. <i>Journal of Hepatology</i> , 1994, 21, 278-279.	3.7	5
139	Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. <i>Journal of Hepatology</i> , 1994, 21, 961-965.	3.7	24
140	Asymptomatic anti-HCV seropositive subjects include patients with chronic active hepatitis and individuals with normal liver: can we distinguish them?. <i>Journal of Hepatology</i> , 1994, 21, 136-137.	3.7	4
141	Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis. <i>Clinical and Diagnostic Virology</i> , 1994, 1, 289-297.	1.7	13
142	Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon α -2a. <i>Gastroenterology</i> , 1994, 107, 479-485.	1.3	42
143	Possible immunopathogenesis for fibrosing cholestatic hepatitis. <i>Gastroenterology</i> , 1994, 106, 822-823.	1.3	3
144	Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. <i>Liver</i> , 1994, 14, 65-70.	0.1	19

#	ARTICLE	IF	CITATIONS
145	Ribavirin treatment for chronic hepatitis D: a pilot study. <i>Liver</i> , 1994, 14, 154-157.	0.1	56
146	Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. <i>Liver</i> , 1994, 14, 175-181.	0.1	57
147	Detection of human androgen receptor mRNA in hepatocellular carcinoma by <i>in situ</i> hybridisation. <i>Liver</i> , 1994, 14, 213-219.	0.1	18
148	Hepatitis B Virus Precore Mutants. , 1994, , 256-260.		1
149	Recombinant interferon- α 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. <i>Hepatology</i> , 1994, 20, 287-290.	7.3	10
150	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	7.3	136
151	Wild-type and HBeAg-minus HBV Fluctuations: Cause or Effect of Chronic Hepatitis B Pathogenic Mechanisms?. , 1994, , 261-264.		0
152	Hepatitis C virus infection and liver disease: Peculiar epidemiological and clinicopathological features. <i>FEMS Microbiology Reviews</i> , 1994, 14, 259-265.	8.6	0
153	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- α 2b. <i>Hepatology</i> , 1993, 18, 1300-1305.	7.3	149
154	Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by <i>in situ</i> hybridization. <i>Journal of Surgical Oncology</i> , 1993, 53, 14-17.	1.7	10
155	Infectious Hepatitis B Virus Variant Defective in Pre-S2 Protein Expression in a Chronic Carrier. <i>Virology</i> , 1993, 194, 137-148.	2.4	141
156	Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. <i>Journal of Hepatology</i> , 1993, 18, 5-8.	3.7	24
157	Colon cancer seeding after percutaneous fine needle aspiration of liver metastasis. <i>Journal of Hepatology</i> , 1993, 18, 276-278.	3.7	39
158	Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. <i>Journal of Hepatology</i> , 1993, 19, 431-436.	3.7	80
159	Hepatitis C virus infection and disease. <i>Journal of Hepatology</i> , 1993, 17, S78-S82.	3.7	17
160	Problems in diagnosing viral hepatitis.. <i>Gut</i> , 1993, 34, S36-S38.	12.1	8
161	Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease?. <i>Journal of Clinical Pathology</i> , 1993, 46, 727-729.	2.0	35
162	Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.. <i>Journal of Experimental Medicine</i> , 1993, 178, 17-25.	8.5	246

#	ARTICLE	IF	CITATIONS
163	T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology, 1993, 104, 580-587.	1.3	331
164	Propafenone-induced liver injury: Report of a case and review of the literature. Gastroenterology, 1993, 104, 1524-1526.	1.3	25
165	Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology, 1993, 105, 845-850.	1.3	190
166	Clinical significance of the antibody to the putative core protein of hepatitis C virus in patients with chronic liver disease. Liver, 1993, 13, 222-226.	0.1	3
167	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- α 2b. Hepatology, 1993, 18, 1300-1305.	7.3	15
168	Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3468-3472.	7.1	723
169	Antibodies to Hepatitis C Virus in Kidney Transplantation. Nephron, 1992, 61, 276-277.	1.8	9
170	Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2247-2251.	7.1	153
171	The epidemiology of hepatitis delta infection in Italy. Journal of Hepatology, 1992, 15, 211-215.	3.7	62
172	Safety of anti-HCV-reactive immunoglobulin in heart transplant patients. Lancet, The, 1992, 340, 1039.	13.7	2
173	Biological standards for hepatitis B virus assays. Journal of Hepatology, 1992, 15, 251-255.	3.7	6
174	Use of interferon in chronic viral hepatitis.. Pharmacological Research, 1992, 26, 96-97.	7.1	0
175	Detection of hepatitis delta virus RNA by a nonradioactive in situ hybridization procedure. Human Pathology, 1992, 23, 557-561.	2.0	18
176	Hepatic endoplasmic reticulum storage diseases. Liver, 1992, 12, 357-362.	0.1	84
177	Dianostic tools from molecular biology. Liver, 1992, 12, 213-216.	0.1	0
178	Variants of hepatitis B virus. Archives of Virology Supplementum, 1992, 4, 83-85.	3.0	0
179	Serology. , 1992, , 128-141.		0
180	Hepatitis Delta virus, a model of liver cell pathology. Journal of Hepatology, 1991, 13, 260-266.	3.7	15

#	ARTICLE	IF	CITATIONS
181	Hepatitis delta virus heterogeneity: a study by immunofluorescence. <i>Journal of Hepatology</i> , 1991, 13, S125-S129.	3.7	18
182	Rabbit-derived anti-HD antibodies for HDAg immunoblotting. <i>Journal of Hepatology</i> , 1991, 13, S130-S133.	3.7	2
183	Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. <i>Journal of Hepatology</i> , 1991, 13, S102-S104.	3.7	49
184	Chronic viral hepatitis. <i>Journal of Hepatology</i> , 1991, 13, S27-S30.	3.7	0
185	Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection. <i>Journal of Hepatology</i> , 1991, 12, 10-13.	3.7	16
186	Sequence variation in hepatitis C viral isolates. <i>Journal of Hepatology</i> , 1991, 13, S6-S14.	3.7	49
187	Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen. <i>Journal of Hepatology</i> , 1991, 13, S8-S11.	3.7	23
188	Hepatitis B virus unable to secrete E antigen. <i>Gastroenterology</i> , 1991, 100, 1138-1141.	1.3	81
189	Patterns of hepatitis delta virus reinfection and disease in liver transplantation. <i>Gastroenterology</i> , 1991, 101, 1649-1655.	1.3	151
190	Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. <i>Virology</i> , 1991, 180, 842-848.	2.4	641
191	Role of hepatitis delta virus infection in hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1134-1136.	2.3	62
192	Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. <i>Hepatology</i> , 1991, 13, 413-416.	7.3	96
193	Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. <i>Hepatology</i> , 1991, 14, 16-24.	7.3	55
194	Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 4186-4190.	7.1	360
195	Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound. <i>Gastroenterology</i> , 1991, 100, 1324-1331.	1.3	78
196	Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. <i>Hepatology</i> , 1991, 13, 413-416.	7.3	6
197	Riboprobe assay for HDV RNA: A sensitive method for the detection of the HDV genome in clinical serum samples. <i>Journal of Medical Virology</i> , 1990, 30, 20-24.	5.0	28
198	A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease. <i>Journal of Medical Virology</i> , 1990, 32, 109-118.	5.0	56

#	ARTICLE	IF	CITATIONS
199	A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. <i>Journal of Hepatology</i> , 1990, 10, 258-261.	3.7	233
200	Detection of hepatitis C viral sequences in non-A, non-B hepatitis. <i>Lancet, The</i> , 1990, 335, 1-3.	13.7	818
201	Immunohistochemical research on HDV infection in Chinese patients with chronic liver disease. <i>Journal of Tongji Medical University</i> , 1989, 9, 5-7.	0.1	7
202	Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. <i>Hepatology</i> , 1989, 10, 198-202.	7.3	230
203	A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. <i>Hepatology</i> , 1989, 10, 336-341.	7.3	96
204	Intrahepatic markers of hepatitis delta virus infection: A study byin Situ hybridization. <i>Hepatology</i> , 1989, 10, 916-920.	7.3	34
205	An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis. <i>Science</i> , 1989, 244, 362-364.	12.6	3,478
206	HEPATITIS C VIRUS: A POSSIBLE CAUSE OF CHRONIC HEPATITIS IN ALCOHOLICS. <i>Lancet, The</i> , 1989, 334, 1390-1391.	13.7	58
207	Serial passage of hepatitis delta virus in chronic hepatitis B virus carrier chimpanzees. <i>Hepatology</i> , 1988, 8, 1655-1661.	7.3	43
208	Delta and non-A, non-B hepatitis viruses. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1988, 7, 327-336.	2.9	2
209	Nucleic acid hybridization in viral Hepatitis research. <i>Research in Clinic and Laboratory</i> , 1988, 18, 121-142.	0.3	0
210	Application Of Nucleic acid hybridization to the hepatitis δ virus research. <i>Research in Clinic and Laboratory</i> , 1988, 18, 143-160.	0.3	0
211	The impact of molecular biology in the diagnosis and management of viral hepatitis. <i>Research in Clinic and Laboratory</i> , 1988, 18, 261-271.	0.3	1
212	Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen. <i>Journal of Hepatology</i> , 1988, 7, 14-20.	3.7	24
213	Chronic HDV (hepatitis delta virus) hepatitis. <i>Journal of Hepatology</i> , 1988, 6, 8-14.	3.7	66
214	INHIBITION OF HEPATITIS B VIRUS REPLICATION BY VIDARABINE MONOPHOSPHATE CONJUGATED WITH LACTOSAMINATED SERUM ALBUMIN. <i>Lancet, The</i> , 1988, 332, 13-15.	13.7	65
215	Hepatitis Delta Virus Infection of the Liver: Progress in Virology, Pathobiology, and Diagnosis. <i>Seminars in Liver Disease</i> , 1988, 8, 350-356.	3.6	37
216	Natural Killer Response to Exogenous Interferon in Delta Hepatitis: Boost or Depression Defined within the First Week of Therapy. <i>Digestion</i> , 1987, 37, 51-58.	2.3	7

#	ARTICLE	IF	CITATIONS
217	Rapidly progressive HBsAg-positive hepatitis in Italy. <i>Journal of Hepatology</i> , 1987, 5, 274-281.	3.7	78
218	Interferon treatment of chronic hepatitis B surface antigen (HBsAg) carriers. A description of the activation profiles of natural killer cells obtained with different schedules of administration in three subsets of carriers. <i>Research in Clinic and Laboratory</i> , 1987, 17, 331-341.	0.3	1
219	Treatment of chronic delta hepatitis with $\hat{1}\pm$ -2 recombinant interferon. <i>Journal of Hepatology</i> , 1986, 3, S229-S233.	3.7	40
220	The importance of hepatitis B viral DNA in serum and liver. <i>Journal of Hepatology</i> , 1986, 3, 136-141.	3.7	34
221	Superimposed hepatitis and the effect on viral replication in chronic hepatitis B. <i>Journal of Hepatology</i> , 1986, 3, S35-S341.	3.7	18
222	Chronic hepatitis in HBsAg carriers with serum HBV-DNA and Anti-HBe. <i>Gastroenterology</i> , 1986, 90, 1268-1273.	1.3	330
223	Type D hepatitis: The clinical significance of hepatitis D virus RNA in serum as detected by a hybridization-based assay. <i>Hepatology</i> , 1986, 6, 1297-1302.	7.3	122
224	A histological study of hepatitis delta virus liver disease. <i>Hepatology</i> , 1986, 6, 1303-1307.	7.3	84
225	Delta Agent (Type D) Hepatitis. <i>Seminars in Liver Disease</i> , 1986, 6, 28-33.	3.6	34
226	Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. <i>Journal of Virology</i> , 1986, 58, 945-950.	3.4	294
227	The spectrum of complement-fixing antinuclear antibodies in patients with hepatocellular carcinoma. <i>Hepatology</i> , 1985, 5, 548-555.	7.3	12
228	Detection of HBV-DNA by in situ hybridization using a biotin-labeled probe. <i>Journal of Medical Virology</i> , 1985, 15, 373-382.	5.0	56
229	Familial clustering and spreading of hepatitis delta virus infection. <i>Journal of Hepatology</i> , 1985, 1, 221-226.	3.7	44
230	Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1984, 81, 2208-2212.	7.1	193
231	Hepatitis B virus DNA (HBVâ€DNA) in antiâ€HBe positive sera. <i>Liver</i> , 1984, 4, 177-183.	0.1	48
232	Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. <i>Infection and Immunity</i> , 1984, 43, 1000-1005.	2.2	140
233	Complexes between hbsag and igm in serum of patients with acute hepatitis. <i>Journal of Medical Virology</i> , 1983, 11, 139-145.	5.0	14
234	Delta hepatitis in inapparent carriers of hepatitis B surface antigen. <i>Gastroenterology</i> , 1983, 85, 669-673.	1.3	78

#	ARTICLE	IF	CITATIONS
235	Chronic Hepatitis in Carriers of Hepatitis B Surface Antigen, with Intrahepatic Expression of the Delta Antigen. <i>Annals of Internal Medicine</i> , 1983, 98, 437.	3.9	351
236	Hepatitis B virus replication and clinical outcome in carriers of HBsAg. Perspectives of treatment with DNA inhibitors. <i>Liver</i> , 1983, 3, 30-35.	0.1	5
237	Complexes of hepatitis B surface antigen and immunoglobulin M in the sera of patients with hepatitis B virus infection. <i>Infection and Immunity</i> , 1983, 41, 950-958.	2.2	20
238	Levamisole and Chronic Delta Hepatitis. <i>Annals of Internal Medicine</i> , 1983, 98, 1024.	3.9	32
239	The $\hat{\Gamma}$ agent: HBsAg particles with $\hat{\Gamma}$ antigen and RNA in the serum of an HBV carrier. <i>Hepatology</i> , 1981, 1, 127-131.	7.3	89
240	Hepatitis B virus DNA in the sera of HBsAg carriers: A marker of active hepatitis B virus replication in the liver. <i>Hepatology</i> , 1981, 1, 386-391.	7.3	312
241	A solid-phase enzyme immunoassay (EIA) for detection of HBeAg and anti-HBe. <i>Journal of Immunological Methods</i> , 1980, 33, 195-200.	1.4	13
242	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. <i>Journal of Medical Virology</i> , 1979, 4, 43-50.	5.0	2
243	Incidence and Significance of Different Types of Connective Tissue Antibodies in Adult and Pediatric Gastroenterological Disorders. <i>Digestion</i> , 1978, 17, 29-37.	2.3	6
244	Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.. <i>Gut</i> , 1977, 18, 997-1003.	12.1	879
245	The immunological diagnosis of HBsAg liver disease by combined screening for thee system in the serum and the HB core and surface antigens in liver biopsy samples. <i>Research in Clinic and Laboratory</i> , 1977, 7, 365-372.	0.3	4
246	Complement fixing hepatitis B core antigen immune complexes in the liver of patients with HBs antigen positive chronic disease.. <i>Gut</i> , 1976, 17, 837-843.	12.1	24
247	Antibodies against the human pancreas in acute and chronic liver disease. <i>Research in Clinic and Laboratory</i> , 1975, 5, 146-158.	0.3	1
248	Pathogenesis of Chronic Hepatitis B. , 0, , 308-322.		2
249	On the operational definition of fatty liver. <i>Qeios</i> , 0, , .	0.0	0